J Cancer 2020; 11(16):4746-4753. doi:10.7150/jca.40089 This issue

Research Paper

SMADs binding site polymorphisms rs9911630 is associated with susceptibility but not prognosis of gastric cancer: a case control study

Liyang Liu1*, Ming Lu1*, Xi Gu1*, Xiang Ma1, Jiaxi Feng1, Yang Cao1, Weida Gong2, Qinghong Zhao1✉, Fulin Qiang3✉

1. Department of General Surgery, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
2. Department of General Surgery, Yixing Tumor Hospital, Yixing, Jiangsu, China.
3. Department of Core Laboratory, Nantong Tumor Hospital, Nantong, Jiangsu, China.
*Equal contributors and co-first authors.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Liu L, Lu M, Gu X, Ma X, Feng J, Cao Y, Gong W, Zhao Q, Qiang F. SMADs binding site polymorphisms rs9911630 is associated with susceptibility but not prognosis of gastric cancer: a case control study. J Cancer 2020; 11(16):4746-4753. doi:10.7150/jca.40089. Available from https://www.jcancer.org/v11p4746.htm

File import instruction

Abstract

Background: Single nucleotide polymorphisms (SNPs) in transcription factor binding sites (TFBS) can change their binding strength, affecting the function of transcription factors (TFs). Small mother against decapentaplegic (SMAD) proteins are known as a family of TFs involved in tumorigenesis. We performed this study to investigate whether SNPs in SMADs binding sites affect the susceptibility or prognosis of gastric cancer (GC).

Methods: Using bioinformatics tools, we focused on the association between rs9911630 polymorphism and GC. We performed this case-control study in 1275 GC patients and 1426 cancer-free subjects using TaqMan allelic discrimination method.

Results: We found that rs9911630 A>G polymorphism was associate to an increased risk of gastric cancer (adjusted OR for additive model = 1.16; 95% CI = 1.03-1.30). Furthermore, we assess whether rs9911630 polymorphism affected the prognosis of GC. However, no significant association was discovered between rs9911630 A>G polymorphism and overall survival time of GC patients (HR for addictive model = 1.01; 95%CI = 0.88-1.15).

Conclusions: Our results suggested that rs9911630 polymorphism in SMADs target site might influence susceptibility but not prognosis of gastric cancer.

Keywords: rs9911630, polymorphisms, susceptibility, gastric cancer